EVO101

Evommune, Inc. · Phase 2 active Small molecule

At a glance

Generic name	EVO101
Sponsor	Evommune, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis (PHASE2)
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1% (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EVO101 CI brief — competitive landscape report
EVO101 updates RSS · CI watch RSS
Evommune, Inc. portfolio CI